Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination.

Despite the importance of downstream bioprocessing, there are many opportunities for improvement, according to a report by Alois Jungbauer, PhD, a retired professor of biotechnology at the University ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...